Cost-effectiveness of subcutaneous pertuzumab, trastuzumab, and hyaluronidase-zzxf for the treatment of high-risk HER2+ early breast cancer.

Jesse Sussell,Joshua A. Roth,Svenn Hansen,Craig S. Meyer,Anita M. Fung

Cost-effectiveness of subcutaneous pertuzumab, trastuzumab, and hyaluronidase-zzxf for the treatment of high-risk HER2+ early breast cancer.

2021

Jesse Sussell
Joshua A. Roth
Svenn Hansen
Craig S. Meyer
Anita M. Fung

e18846Background: Standard therapy for high-risk HER2+ early breast cancer (EBC) begins with neoadjuvant dual targeted therapy with pertuzumab (P) + trastuzumab (T) + chemotherapy (CTX). After surg...

Keywords:

Targeted therapy
cost effectiveness
Medicine
Internal medicine
Trastuzumab
Chemotherapy
Hyaluronidase
Oncology
standard therapy
Pertuzumab
early breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations